CSF neopterin and beta-2-microglobulin as inflammation biomarkers in newborns with hypoxic-ischemic encephalopathy.
Journal
Pediatric research
ISSN: 1530-0447
Titre abrégé: Pediatr Res
Pays: United States
ID NLM: 0100714
Informations de publication
Date de publication:
04 2023
04 2023
Historique:
received:
07
07
2021
accepted:
15
02
2022
revised:
01
02
2022
medline:
28
4
2023
pubmed:
8
4
2022
entrez:
7
4
2022
Statut:
ppublish
Résumé
Inflammation plays a crucial role in the pathogenesis of hypoxic-ischemic encephalopathy (HIE). The aim of this study was to measure inflammation in HIE through an analysis of CSF neopterin and β2-microglobulin and to study the association with brain injury as shown by MRI findings and neurodevelopmental outcomes. CSF biomarkers were measured in study patients at 12 and 72 h. Brain injury was evaluated by MRI, and neurodevelopmental outcomes were assessed at 2-3 years of life. An adverse outcome was defined as the presence of motor or cognitive impairment. Sixty-nine HIE infants were included. Median values of neopterin and β2-microglobulin paralleled the severity of HIE. Adverse outcomes were associated with early neopterin and β2-microglobulin values, late neopterin values, and the neopterin percentage change between the two samples. A cutoff value of 75% neopterin change predicted adverse outcomes with a specificity of 0.9 and a sensitivity of 0.75. CSF neopterin and β2-microglobulin are elevated in HIE, indicating the activation of inflammation processes. Infants with adverse neurodevelopmental outcomes show higher levels of CSF neopterin and β2-microglobulin. The evolution of neopterin levels provides a better predictive capacity than a single determination. Brain inflammation in newborns with HIE could be measurable through the analysis of CSF neopterin and β2-microglobulin, both of which are associated with neurodevelopmental outcomes. Our study introduces two inflammatory biomarkers for infants with HIE that seem to show a more stable profile and are easier to interpret than cytokines. CSF neopterin and β2-m may become clinical tools to monitor inflammation in HIE and might eventually be helpful in measuring the response to emerging therapies.
Sections du résumé
BACKGROUND
Inflammation plays a crucial role in the pathogenesis of hypoxic-ischemic encephalopathy (HIE). The aim of this study was to measure inflammation in HIE through an analysis of CSF neopterin and β2-microglobulin and to study the association with brain injury as shown by MRI findings and neurodevelopmental outcomes.
METHODS
CSF biomarkers were measured in study patients at 12 and 72 h. Brain injury was evaluated by MRI, and neurodevelopmental outcomes were assessed at 2-3 years of life. An adverse outcome was defined as the presence of motor or cognitive impairment.
RESULTS
Sixty-nine HIE infants were included. Median values of neopterin and β2-microglobulin paralleled the severity of HIE. Adverse outcomes were associated with early neopterin and β2-microglobulin values, late neopterin values, and the neopterin percentage change between the two samples. A cutoff value of 75% neopterin change predicted adverse outcomes with a specificity of 0.9 and a sensitivity of 0.75.
CONCLUSIONS
CSF neopterin and β2-microglobulin are elevated in HIE, indicating the activation of inflammation processes. Infants with adverse neurodevelopmental outcomes show higher levels of CSF neopterin and β2-microglobulin. The evolution of neopterin levels provides a better predictive capacity than a single determination.
IMPACT
Brain inflammation in newborns with HIE could be measurable through the analysis of CSF neopterin and β2-microglobulin, both of which are associated with neurodevelopmental outcomes. Our study introduces two inflammatory biomarkers for infants with HIE that seem to show a more stable profile and are easier to interpret than cytokines. CSF neopterin and β2-m may become clinical tools to monitor inflammation in HIE and might eventually be helpful in measuring the response to emerging therapies.
Identifiants
pubmed: 35388137
doi: 10.1038/s41390-022-02011-0
pii: 10.1038/s41390-022-02011-0
doi:
Substances chimiques
Neopterin
670-65-5
Biomarkers
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1328-1335Informations de copyright
© 2022. The Author(s), under exclusive licence to the International Pediatric Research Foundation, Inc.
Références
Tagin, M. A., Woolcott, C. G., Vincer, M. J., Whyte, R. K. & Stinson, D. A. Hypothermia for neonatal hypoxic ischemic encephalopathy: an updated systematic review and meta-analysis. Arch. Pediatr. Adolesc. Med. 166, 558–566 (2012).
doi: 10.1001/archpediatrics.2011.1772
pubmed: 22312166
Jacobs, S. E. et al. Cooling for newborns with hypoxic ischaemic encephalopathy. Cochrane Database Syst. Rev. 1, CD003311 (2013).
Drury, P. P., Gunn, E. R., Bennet, L. & Gunn, A. J. Mechanisms of hypothermic neuroprotection. Clin. Perinatol. 41, 161–175 (2014).
doi: 10.1016/j.clp.2013.10.005
pubmed: 24524453
Hagberg, H. et al. The role of inflammation in perinatal brain injury. Nat. Rev. Neurol. 11, 192–208 (2015).
doi: 10.1038/nrneurol.2015.13
pubmed: 25686754
pmcid: 4664161
Davidson, J. O. et al. Perinatal brain injury: mechanisms and therapeutic approaches. Front. Biosci. 23, 2204–2226 (2018).
doi: 10.2741/4700
Pang, R. et al. Elevated serum IL-10 is associated with severity of neonatal encephalopathy and adverse early childhood outcomes. Pediatr. Res. https://doi.org/10.1038/s41390-021-01438-1 (2021).
Orrock, J. E. et al. Association of brain injury and neonatal cytokine response during therapeutic hypothermia in newborns with hypoxic-ischemic encephalopathy. Pediatr. Res. 79, 742–747 (2016).
doi: 10.1038/pr.2015.280
pubmed: 26717001
Jenkins, D. D. et al. Serum cytokines in a clinical trial of hypothermia for neonatal hypoxic-ischemic encephalopathy. J. Cereb. Blood Flow Metab. 32, 1888–1896 (2012).
doi: 10.1038/jcbfm.2012.83
pubmed: 22805873
pmcid: 3463879
Martín-Ancel, A. et al. Interleukin-6 in the cerebrospinal fluid after perinatal asphyxia is related to early and late neurological manifestations. Pediatrics 100, 789–794 (1997).
doi: 10.1542/peds.100.5.789
pubmed: 9346977
Sävman, K., Blennow, M., Gustafson, K., Tarkowski, E. & Hagberg, H. Cytokine response in cerebrospinal fluid after birth asphyxia. Pediatr. Res. 43, 746–751 (1998).
doi: 10.1203/00006450-199806000-00006
pubmed: 9621983
Ahearne, C. E., Chang, R. Y., Walsh, B. H., Boylan, G. B. & Murray, D. M. Cord blood IL-16 is associated with 3-year neurodevelopmental outcomes in perinatal asphyxia and hypoxic-ischaemic encephalopathy. Dev. Neurosci. 39, 59–65 (2017).
doi: 10.1159/000471508
pubmed: 28490023
Hoffmann, G., Wirleitner, B. & Fuchs, D. Potential role of immune system activation-associated production of neopterin derivatives in humans. Inflamm. Res. 52, 313–321 (2003).
doi: 10.1007/s00011-003-1181-9
pubmed: 14504669
Furukawa, Y., Nishi, K., Kondo, T., Tanabe, K. & Mizuno, Y. Significance of CSF total neopterin and biopterin in inflammatory neurological diseases. J. Neurol. Sci. 111, 65–72 (1992).
doi: 10.1016/0022-510X(92)90113-Y
pubmed: 1402999
Millner, M. M. et al. Neopterin concentrations in cerebrospinal fluid and serum as an aid in differentiating central nervous system and peripheral infections in children. Clin. Chem. 44, 161–167 (1998).
doi: 10.1093/clinchem/44.1.161
pubmed: 9550574
Dale, R. C., Brilot, F., Fagan, E. & Earl, J. Cerebrospinal fluid neopterin in paediatric neurology: a marker of active central nervous system inflammation. Dev. Med. Child Neurol. 51, 317–323 (2009).
doi: 10.1111/j.1469-8749.2008.03225.x
pubmed: 19191826
Hagberg, L. et al. Cerebrospinal fluid neopterin: an informative biomarker of central nervous system immune activation in HIV-1 infection. AIDS Res. Ther. 7, 15 (2010).
doi: 10.1186/1742-6405-7-15
pubmed: 20525234
pmcid: 2890504
Tiberti, N. et al. Neopterin is a cerebrospinal fluid marker for treatment outcome evaluation in patients affected by Trypanosoma brucei gambiense sleeping sickness. PLoS Negl. Trop. Dis. 7, e2088 (2013).
doi: 10.1371/journal.pntd.0002088
pubmed: 23469311
pmcid: 3585011
Bernier, G. M. beta 2-Microglobulin: structure, function and significance. Vox Sang. 38, 323–327 (1980).
pubmed: 6159720
Tagarro, A., García-Alix, A., Alarcón, A., Hernanz, A. & Quero, J. Congenital syphilis: beta2-microglobulin in cerebrospinal fluid and diagnosis of neurosyphilis in an affected newborn. J. Perinat. Med. 33, 79–82 (2005).
doi: 10.1515/JPM.2005.015
pubmed: 15841621
Alarcon, A. et al. Clinical, biochemical, and neuroimaging findings predict long-term neurodevelopmental outcome in symptomatic congenital cytomegalovirus infection. J. Pediatr. 163, 828.e1–834.e1 (2013).
doi: 10.1016/j.jpeds.2013.03.014
Alarcon, A. et al. Beta2-microglobulin concentrations in cerebrospinal fluid correlate with neuroimaging findings in newborns with symptomatic congenital cytomegalovirus infection. Eur. J. Pediatr. 165, 636–645 (2006).
doi: 10.1007/s00431-006-0160-x
pubmed: 16691400
García-Alix, A. et al. Cerebrospinal fluid beta 2-microglobulin in neonates with central nervous system infections. Eur. J. Pediatr. 154, 309–313 (1995).
doi: 10.1007/s004310050295
pubmed: 7607283
Svatoňová, J., Bořecká, K., Adam, P. & Lánská, V. Beta2-microglobulin as a diagnostic marker in cerebrospinal fluid: a follow-up study. Dis. Markers 2014, 495402 (2014).
doi: 10.1155/2014/495402
pubmed: 24895473
pmcid: 4034398
Garcia-Alix, A. et al. Development, reliability, and testing of a new rating scale for neonatal encephalopathy. J. Pediatr. 235, 83.e7–91.e7 (2021).
doi: 10.1016/j.jpeds.2021.04.003
Ormazabal, A. et al. HPLC with electrochemical and fluorescence detection procedures for the diagnosis of inborn errors of biogenic amines and pterins. J. Neurosci. Methods 142, 153–158 (2005).
doi: 10.1016/j.jneumeth.2004.08.007
pubmed: 15652629
Rutherford, M. et al. Assessment of brain tissue injury after moderate hypothermia in neonates with hypoxic-ischaemic encephalopathy: a nested substudy of a randomised controlled trial. Lancet Neurol. 9, 39–45 (2010).
doi: 10.1016/S1474-4422(09)70295-9
pubmed: 19896902
pmcid: 2795146
Martinez-Biarge, M. et al. Predicting motor outcome and death in term hypoxic-ischemic encephalopathy. Neurology 76, 2055–2061 (2011).
doi: 10.1212/WNL.0b013e31821f442d
pubmed: 21670434
pmcid: 3111238
Albers, C. A. & Grieve, A. J. Test review: Bayley, N. (2006). Bayley Scales of Infant and Toddler Development–Third Edition. San Antonio, TX: Harcourt Assessment. J. Psychoeduc. Assess. 25, 180–190 (2007).
Surveillance of Cerebral Palsy in Europe. Surveillance of cerebral palsy in Europe: a collaboration of cerebral palsy surveys and registers. Surveillance of Cerebral Palsy in Europe (SCPE). Dev. Med. Child Neurol. 42, 816–824 (2000).
doi: 10.1017/S0012162200001511
Palisano, R. et al. Development and reliability of a system to classify gross motor function in children with cerebral palsy. Dev. Med. Child Neurol. 39, 214–223 (1997).
doi: 10.1111/j.1469-8749.1997.tb07414.x
pubmed: 9183258
Freeman, S. WPPSI-III – Wechsler Preschool and Primary Scale of Intelligence, Third Edition in Encyclopedia of Autism Spectrum Disorders (ed. Volkmar, F. R.) 3400 (Springer New York, 2013).
Grizzle, R. in Encyclopedia of Child Behavior and Development (eds Goldstein, S. & Naglieri, J. A.) 1553–1555 (Springer US, 2011).
Brown, T. in Encyclopedia of Autism Spectrum Disorders (ed. Volkmar, F. R.) 1925–1939 (Springer New York, 2013).
León-Lozano, M. Z. et al. Cerebrospinal fluid levels of neuron-specific enolase predict the severity of brain damage in newborns with neonatal hypoxic-ischemic encephalopathy treated with hypothermia. PLoS ONE 15, e0234082 (2020).
Chalak, L. F. Inflammatory biomarkers of birth asphyxia. Clin. Perinatol. 43, 501–510 (2016).
doi: 10.1016/j.clp.2016.04.008
pubmed: 27524450
pmcid: 6170165
Wintermark, P., Boyd, T., Gregas, M. C., Labrecque, M. & Hansen, A. Placental pathology in asphyxiated newborns meeting the criteria for therapeutic hypothermia. Am. J. Obstet. Gynecol. 203, 579.e1–579.e9 (2010).
Mir, I. N. et al. Placental pathology is associated with severity of neonatal encephalopathy and adverse developmental outcomes following hypothermia. Am. J. Obstet. Gynecol. 213, 849.e1–849.e7 (2015).
doi: 10.1016/j.ajog.2015.09.072
pubmed: 26408082
Osredkar, D. et al. Hypothermia is not neuroprotective after infection-sensitized neonatal hypoxic–ischemic brain injury. Resuscitation 85, 567–572 (2014).
doi: 10.1016/j.resuscitation.2013.12.006
pubmed: 24361672
Balada, R. et al. Enquiring beneath the surface: can a gene expression assay shed light into the heterogeneity among newborns with neonatal encephalopathy? Pediatr. Res. 88, 451–458 (2020).
doi: 10.1038/s41390-020-0764-2
pubmed: 31952072
Suzuki, S., Tanaka, K. & Suzuki, N. Ambivalent aspects of interleukin-6 in cerebral ischemia: Inflammatory versus neurotrophic aspects. J. Cereb. Blood Flow Metab. 29, 464–479 (2009).
doi: 10.1038/jcbfm.2008.141
pubmed: 19018268
Sweetman, D. U. et al. Neonatal encephalopathy is associated with altered IL-8 and GM-CSF which correlates with outcomes. Front. Pediatr. 8, 556216 (2021).
doi: 10.3389/fped.2020.556216
pubmed: 33628760
pmcid: 7899044
Kleuskens, D. G. et al. Pathophysiology of cerebral hyperperfusion in term neonates with hypoxic-ischemic encephalopathy: a systematic review for future research. Front. Pediatr. 9, 631258 (2021).
Wu, Y. W. et al. High-dose erythropoietin and hypothermia for hypoxic-ischemic encephalopathy: a phase II trial. Pediatrics 137, e20160191 (2016).
Robertson, N. J. et al. Melatonin as an adjunct to therapeutic hypothermia in a piglet model of neonatal encephalopathy: a translational study. Neurobiol. Dis. 121, 240–251 (2019).
doi: 10.1016/j.nbd.2018.10.004
pubmed: 30300675
Hanson, A. L., Schunk, J. E., Corneli, H. M. & Soprano, J. V. A randomized controlled trial of positioning for lumbar puncture in young infants. Pediatr. Emerg. Care 32, 504–507 (2016).
doi: 10.1097/PEC.0000000000000469
pubmed: 26417957